1. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Issue 12 (December 2016) Authors: Gettinger, Scott N; Bazhenova, Lyudmila A; Langer, Corey J; Salgia, Ravi; Gold, Kathryn A; Rosell, Rafael; Shaw, Alice T; Weiss, Glen J; Tugnait, Meera; Narasimhan, Narayana I; Dorer, David J; Kerstein, David; Rivera, Victor M; Clackson, Timothy; Haluska, Frank G; Camidge, David Ross Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: 1683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Issue 4 (April 2016) Authors: Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Jürgen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, S... Journal: Lancet oncology Issue: Volume 17:Issue 4(2016:Apr.) Page Start: 452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Issue 2 (February 2016) Authors: Shaw, Alice T; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J; Cetnar, Jeremy; West, Howard; Camidge, D Ross; Socinski, Mark A; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H; Borghaei, Hossein; Gold, Kathryn A; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou... Journal: Lancet oncology Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Issue 7 (July 2017) Authors: Shaw, Alice T; Kim, Tae Min; Crinò, Lucio; Gridelli, Cesare; Kiura, Katsuyuki; Liu, Geoffrey; Novello, Silvia; Bearz, Alessandra; Gautschi, Oliver; Mok, Tony; Nishio, Makoto; Scagliotti, Giorgio; Spigel, David R; Deudon, Stéphanie; Zheng, Cheng; Pantano, Serafino; Urban, Patrick; Massacesi, Crist... Journal: Lancet oncology Issue: Volume 18:Issue 7(2017:Jul.) Page Start: 874 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Issue 4 (April 2023) Authors: Solomon, Benjamin J; Bauer, Todd M; Mok, Tony S K; Liu, Geoffrey; Mazieres, Julien; de Marinis, Filippo; Goto, Yasushi; Kim, Dong-Wan; Wu, Yi-Long; Jassem, Jacek; López, Froylán López; Soo, Ross A; Shaw, Alice T; Polli, Anna; Messina, Rossella; Iadeluca, Laura; Toffalorio, Francesca; Felip, Enriq... Journal: Lancet Issue: Volume 11:Issue 4(2023) Page Start: 354 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Issue 2 (February 2020) Authors: Doebele, Robert C; Drilon, Alexander; Paz-Ares, Luis; Siena, Salvatore; Shaw, Alice T; Farago, Anna F; Blakely, Collin M; Seto, Takashi; Cho, Byung Chul; Tosi, Diego; Besse, Benjamin; Chawla, Sant P; Bazhenova, Lyudmila; Krauss, John C; Chae, Young Kwang; Barve, Minal; Garrido-Laguna, Ignacio; Li... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Issue 2 (February 2020) Authors: Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G; Shaw, Alice T; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jürgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R; Chiu, Chao-Hua; John, Thomas; Goto, Koichi; Karapetis, Christos S; Arken... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Issue 10089 (1st July 2017) Authors: Gainor, Justin F; Shaw, Alice T Journal: Lancet Issue: Volume 390:Issue 10089(2017) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Issue 12 (December 2019) Authors: Shaw, Alice T; Solomon, Benjamin J; Chiari, Rita; Riely, Gregory J; Besse, Benjamin; Soo, Ross A; Kao, Steven; Lin, Chia-Chi; Bauer, Todd M; Clancy, Jill S; Thurm, Holger; Martini, Jean-Francois; Peltz, Gerson; Abbattista, Antonello; Li, Sherry; Ou, Sai-Hong Ignatius Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1691 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Issue 12 (December 2017) Authors: Shaw, Alice T; Felip, Enriqueta; Bauer, Todd M; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F; Johnson, Melissa; Dietrich, Jorg; James, Leonard P; Clancy, Jill S; Chen, Joseph; Martini, Jean-François; Abbattista, Antonello; Solomon, Benjamin J Journal: Lancet oncology Issue: Volume 18:Issue 12(2017:Dec.) Page Start: 1590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗